FDA Shares Insights On Potential Pathway To Regulate CBD Products

The Food and Drug Administration (FDA) held a stakeholder call on May 25, 2023 to provide additional information related to the agency's January 26 announcement that it believes a new regulatory framework for cannabidiol (CBD) products is needed. FDA has regulatory authority over a variety of products (including food, drugs, medical devices, dietary supplements, cosmetics, and tobacco products) but as we explained previously, FDA has identified risks associated with the use of CBD in certain products that it does not believe it can effectively manage under its current regulatory authorities. For example, FDA has determined that CBD cannot be safely used as an ingredient in food and dietary supplements under the current regime and that a new framework is also needed to ensure that inhalable hemp products are subject to FDA regulation. So, the agency is working with Congress to develop a new pathway that provides appropriate safeguards and oversight to manage and